Citadel Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-101,329
Closed -$468K 10296
2019
Q1
$468K Buy
+101,329
New +$480K ﹤0.01% 6904
2018
Q2
Sell
-64,978
Closed -$453K 9550
2018
Q1
$392K Sell
64,978
-92,868
-59% -$767K ﹤0.01% 6297
2017
Q4
$1.52M Sell
157,846
-25,900
-14% -$170K ﹤0.01% 4016
2017
Q3
$1.63M Buy
183,746
+112,338
+157% +$1.16M ﹤0.01% 3654
2017
Q2
$903K Buy
71,408
+53,310
+295% +$631K ﹤0.01% 4233
2017
Q1
$190K Sell
18,098
-54,488
-75% -$581K ﹤0.01% 6562
2016
Q4
$668K Sell
72,586
-315,097
-81% -$3.56M ﹤0.01% 4458
2016
Q3
$4.57M Buy
+387,683
New +$5.89M ﹤0.01% 2073
2016
Q1
Sell
-446,129
Closed -$8.47M 8592
2015
Q4
$12.8M Sell
446,129
-520,288
-54% -$14.4M 0.01% 1099
2015
Q3
$27.5M Buy
966,417
+767,504
+386% +$28.2M 0.03% 706
2015
Q2
$7.14M Buy
198,913
+52,997
+36% +$1.65M 0.01% 1720
2015
Q1
$4.24M Buy
145,916
+118,510
+432% +$3.13M ﹤0.01% 2196
2014
Q4
$577K Sell
27,406
-19,386
-41% -$383K ﹤0.01% 4518
2014
Q3
$907K Sell
46,792
-18,230
-28% -$286K ﹤0.01% 3831
2014
Q2
$1.01M Buy
65,022
+28,370
+77% +$459K ﹤0.01% 3468
2014
Q1
$760K Sell
36,652
-67,253
-65% -$1.33M ﹤0.01% 3779
2013
Q4
$1.34M Buy
103,905
+77,232
+290% +$1.07M ﹤0.01% 2929
2013
Q3
$311K Buy
+26,673
New +$219K ﹤0.01% 4305

Other funds holding INSY

Citadel Advisors's INSY Position: Q2 2019 in Review

Citadel Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 101,329 shares — an estimated $468K sold.

Citadel Advisors first reported a position in INSY in Q3 2013 and held it in 18 quarters. The position peaked at $27.5M in Q3 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Citadel Advisors reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Citadel Advisors sold 101,329 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $468K.
  • Citadel Advisors first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 18 quarters.
  • Citadel Advisors's Insys Therapeutics, Inc. position peaked at $27.5M in Q3 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Citadel Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.